Evidence map›Paper›PMID 35199306›Full record

ArticleTissue engineering and regenerative medicine2022

Chitosan Scaffold Containing Periostin Enhances Sternum Bone Healing and Decreases Serum Level of TNF-α and IL-6 after Sternotomy in Rat.

Mehdi Salehiamin, Heidar Toolee, Mahmoud Azami, Seyed Hossein Ahmadi Tafti, Sina Mojaverrostami, Shahnaz Halimi, Shogoofa Barakzai, Aligholi Sobhani, Yasaman Abbasi

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering and regenerative medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mehdi SalehiaminDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Heidar TooleeSchool of Allied Medical Sciences, Shahroud University of Medical Sciences, Shahroud, Iran.
Mahmoud AzamiDepartment of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Hossein Ahmadi TaftiResearch Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Sina MojaverrostamiDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Shahnaz HalimiDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Shogoofa BarakzaiDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Aligholi SobhaniDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. sobhania@tums.ac.ir.ORCID 0000-0002-7175-1827
Yasaman AbbasiSchool of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRShahroud University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the aftermath of bone injuries, such as cranium and sternum, bone wax (BW) is used to control bleeding from the bone surfaces during surgery. Made up of artificial substances, however, it is associated with many complications such as inflammation, increased risk for infection, and bone repair delay. We, therefore, in this study set out to design and evaluate a novel BW without the above-mentioned side-effects reported for other therapies.

methodsThe pastes (new BW(s)) were prepared in the laboratory and examined by MTT, MIC, MBC, and degradability tests. Then, 60 adult male Wistar rats, divided into six equal groups including chitosan (CT), CT-octacalcium phosphate (OCP), CT-periostin (Post), CT-OCP-Post, Control (Ctrl), and BW, underwent sternotomy surgery. Once the surgeries were completed, the bone repair was assessed radiologically and thereafter clinically in vivo and in vitro using CT-scan, H&E, ELISA, and qRT-PCR.

resultsAll pastes displayed antibacterial properties and the CT-Post group had the highest cell viability compared to the control group. In contrast to the BW, CT-Post group demonstrated weight changes in the degradability test. In the CT-Post group, more number of osteocyte cells, high trabeculae percentage, and the least fibrous connective tissue were observed compared to other groups. Additionally, in comparison to the CT and Ctrl groups, higher alkaline phosphatase activity, as well as decreased level of serum tumor necrosis factor-α, interleukin-6, and OCN in the CT-Post group was evident. Finally, Runx2, OPG, and RANKL genes' expression was significantly higher in the CT-Post group than in other groups.

conclusionOur results provide insights into the desirability of pastes in terms of cellular viability, degradability, antibacterial properties, and surgical site restoration compared to the BW group. Besides, Periostin could enhance the osteogenic properties of bone tissue defect site.

Indexed as

Biocompatible MaterialsCell Adhesion MoleculesChitosanSternumAnimalsAnti-Bacterial AgentsInterleukin-6MaleRatsRats, WistarSternotomyTissue ScaffoldsTumor Necrosis Factor-alphaAnti-Bacterial AgentsBiocompatible MaterialsCell Adhesion MoleculesChitosanInterleukin-6Tumor Necrosis Factor-alphaBone healingChitosanOPG and RANKLPeriostinRunx2

Identifiers

PMID35199306
PMCPMC9294132
OpenAlexW4213432372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.